These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 30683678)

  • 41. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
    Guerry MJ; Vanhille P; Ronco P; Debiec H
    Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
    [No Abstract]   [Full Text] [Related]  

  • 42. An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
    Maas R; Hofstra JM; Wetzels JF
    Minerva Med; 2012 Aug; 103(4):253-66. PubMed ID: 22805618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P; Remuzzi G; Ruggenenti P
    Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mercury Intoxication as a Rare Cause of Membranous Nephropathy in a Child.
    Onwuzuligbo O; Hendricks AR; Hassler J; Domanski K; Goto C; Wolf MTF
    Am J Kidney Dis; 2018 Oct; 72(4):601-605. PubMed ID: 30041877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Membranous nephropathy.
    Ronco P; Beck L; Debiec H; Fervenza FC; Hou FF; Jha V; Sethi S; Tong A; Vivarelli M; Wetzels J
    Nat Rev Dis Primers; 2021 Sep; 7(1):69. PubMed ID: 34593809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Membranous Nephropathy (MN) Recurrence After Renal Transplantation.
    Passerini P; Malvica S; Tripodi F; Cerutti R; Messa P
    Front Immunol; 2019; 10():1326. PubMed ID: 31244861
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
    Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
    Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan.
    Shiiki H; Saito T; Nishitani Y; Mitarai T; Yorioka N; Yoshimura A; Yokoyama H; Nishi S; Tomino Y; Kurokawa K; Sakai H;
    Kidney Int; 2004 Apr; 65(4):1400-7. PubMed ID: 15086481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: a case report.
    Taguchi S; Koshikawa Y; Ohyama S; Miyachi H; Ozawa H; Asada H
    BMC Nephrol; 2019 Feb; 20(1):43. PubMed ID: 30727973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ACTH and azathioprine: antiproteinuric and lipid-lowering effect in the course of idiopathic membranous glomerulonephritis.
    Gigante A; Rosato E; Liberatori M; Gasperini ML; Giannakakis K; Barbano B; Cianci R; Salsano F; Amoroso A
    J Biol Regul Homeost Agents; 2012; 26(1):135-8. PubMed ID: 22475105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Membranous nephropathy and crescentic glomerulonephritis].
    Vozmediano C; Sánchez de la Nieta MD; González L; Alvarez T; de la Torre M; Blanco J; Nieto J; Rivera F
    Nefrologia; 2005; 25(3):328-31. PubMed ID: 16053015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prognosis of chronic renal failure in patients with membranous nephropathy].
    Razukeviciene L; Kuzminskis V; Bumblyte IA; Laurinavicius A
    Medicina (Kaunas); 2003; 39 Suppl 1():9-15. PubMed ID: 12761414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Membranous glomerulonephritis: better therapy with autoantibody monitoring?].
    Stahl RA; Hoxha E; Helmchen U
    Dtsch Med Wochenschr; 2011 Aug; 136(34-35):1733-7. PubMed ID: 21877306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent advances and prognosis in idiopathic membranous nephropathy.
    Segal PE; Choi MJ
    Adv Chronic Kidney Dis; 2012 Mar; 19(2):114-9. PubMed ID: 22449349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.
    Maharjan R; Wang JW; Shrestha IK
    J Nepal Health Res Counc; 2021 Jan; 18(4):580-587. PubMed ID: 33510493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
    Fenoglio R; Baldovino S; Sciascia S; De Simone E; Del Vecchio G; Ferro M; Quattrocchio G; Naretto C; Roccatello D
    J Nephrol; 2021 Apr; 34(2):565-571. PubMed ID: 32594370
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
    van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
    Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
    [No Abstract]   [Full Text] [Related]  

  • 60. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.